Study of FCN-098 in Patients With Advanced Solid Tumor

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

May 8, 2024

Study Completion Date

October 12, 2024

Conditions

Solid Tumor

Interventions

DRUG

FCN-098

FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai